Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 14/20 | 0.44 |
| ▸ | CRHR2 | Q13324 | 3/20 | 0.44 |
| ▸ | DRD4 | P21917 | 1/20 | 0.43 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.38 |
| ▸ | PDE4A | P27815 | 1/20 | 0.38 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.38 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.38 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22776463 | 1.00 | CRHR1 (0.44) | CRHR1CRHR2DRD4SLC6A5SIGMAR1 | |
| SCHEMBL29614440 | 1.00 | CRHR1 (0.44) | CRHR1CRHR2DRD4SLC6A5SIGMAR1 | |
| SCHEMBL22777347 | 0.90 | CRHR1 (0.42) | CRHR1CRHR2DRD4SLC6A5 | |
| SCHEMBL29614517 | 0.90 | CRHR1 (0.42) | CRHR1CRHR2DRD4SLC6A5 | |
| SCHEMBL22777346 | 0.90 | CRHR1 (0.42) | CRHR1CRHR2DRD4SLC6A5 | |
| SCHEMBL22791216 | 0.89 | DRD4 (0.46) | CRHR1CRHR2DRD4SLC6A5 | |
| SCHEMBL22776428 | 0.82 | PTGER4 (0.49) | CRHR1CRHR2DRD4SLC6A5SIGMAR1 | |
| SCHEMBL29614505 | 0.82 | PTGER4 (0.49) | CRHR1CRHR2DRD4SLC6A5SIGMAR1 | |
| SCHEMBL22776427 | 0.82 | PTGER4 (0.49) | CRHR1CRHR2DRD4SLC6A5SIGMAR1 | |
| SCHEMBL22776576 | 0.81 | PTGER4 (0.48) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220324803-A1 | PROSTAGLANDIN E2 RECEPTOR 4 ANTAGONISTS AND USES THEREOF | TEON THERAPEUTICS INC (US) | 2022-10-13 | — | — | US | disclosed |
| EP-3983412-A1 | PROSTAGLANDIN E2 RECEPTOR 4 ANTAGONISTS AND USES THEREOF | Teon Therapeutics, Inc. (US) | 2022-04-20 | — | — | EP | disclosed |
| CN-114206866-A | Prostaglandin E2Receptor 4 antagonists and uses thereof | 泰昂治疗公司 | 2022-03-18 | — | — | CN | disclosed |
| WO-2020251957-A1 | PROSTAGLANDIN E2 RECEPTOR 4 ANTAGONISTS AND USES THEREOF | TEON THERAPEUTICS, INC. (US) | 2020-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220324803-A1 | PROSTAGLANDIN E2 RECEPTOR 4 ANTAGONISTS AND USES THEREOF | PTGER4, PTGER1, PTGER2 | CRHR1 386/4885CRHR2 226/4885DRD4 2226/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.